Altamira Therapeutics (CYTO) Corporate presentation summary

Technology platform and innovation

• Proprietary peptide-based nanoparticle platforms (OligoPhore, Semaphore, Cyclophore, GenePhore) enable efficient delivery of various RNA modalities beyond the liver, targeting extrahepatic tissues and inflamed pathological sites.

• Nanoparticles provide high stability, selectivity, and safety, with efficient endosomal escape and no observed immune response or organ toxicity in preclinical models.

• Demonstrated 10-fold higher release within target cells compared to lipid nanoparticles, the current industry standard.

• Technology is suitable for siRNA, mRNA, circRNA, and DNA, and has been tested in 17 disease models.

Flagship programs and pipeline

• Two lead programs: AM-401 for KRAS-driven cancers and AM-411 for rheumatoid arthritis, both targeting IND submission in 2026.

• AM-401 targets multiple KRAS mutations, offering polyvalent coverage and reduced resistance by degrading mRNA, with preclinical data showing significant tumor volume reduction.

• AM-411 targets NF-κB in inflamed tissues, aiming to reduce systemic side effects and resistance in rheumatoid arthritis, with preclinical efficacy in reducing inflammation and bone erosion.

• Additional in vivo proof-of-concept in oncology, inflammatory, and metabolic disease models.

Market opportunity and growth

• RNA therapeutics market is rapidly expanding, with mRNA therapeutics projected to reach $101.3B and siRNA therapeutics $11B by 2026, both with double-digit CAGR.

• High unmet medical needs in targeted indications, such as KRAS-driven cancers and rheumatoid arthritis, with large addressable markets.

• Active M&A and licensing environment, with platform strategy focused on partnering and out-licensing.